Latest news with #JoelGrade
Yahoo
03-08-2025
- Business
- Yahoo
Baxter International (BAX) Falls to New Low on Disappointing Growth Forecast
We recently published . Baxter International Inc. (NYSE:BAX) is one of the worst-performing stocks on Thursday. Baxter International dropped its share prices to a new 52-week low on Thursday, as investors soured on its lower earnings growth forecast. At intra-day trading, shares of Baxter International Inc. (NYSE:BAX) dropped to their lowest price of $21.47 before ending the day down by 22.42 percent at $21.76 apiece. In a call with analysts, Baxter International Inc. (NYSE:BAX) said it lowered its adjusted EPS to between $2.42 and $2.52 from the $2.47 to $2.55. Analysts expected $2.52 per share. 'While we never want to lower expectations, our overall objective is reducing the outlook to capture more of the potential downside risks,' Baxter International Inc. (NYSE:BAX) CFO Joel Grade was quoted as saying, underscoring the demand weakness for IV fluids. Pixabay / Public Domain In the second quarter of the year, Baxter International Inc. (NYSE:BAX) swung to a net income attributable to shareholders of $91 million from a $314 million net loss in the same period last year. Net sales inched up by 4 percent to $2.8 billion from $2.69 billion. While we acknowledge the potential of BAX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Reuters
31-07-2025
- Business
- Reuters
Medical products maker Baxter cuts 2025 forecast; shares plunge to 19-year low
July 31 (Reuters) - Baxter International (BAX.N), opens new tab slashed its 2025 profit forecast and posted disappointing quarterly earnings on Thursday, as lingering fallout from Hurricane Helene and continued hospital fluid conservation weighed on its medical products business. Shares of the medical products maker tumbled about 23% in morning trading, hitting their lowest level since 2006. Noting the "softness in demand" for IV fluids - used to deliver medications or nutrients directly into a patient's bloodstream - CFO Joel Grade told analysts, "While we never want to lower expectations, our overall objective is reducing the outlook to capture more of the potential downside risks." Baxter has voluntarily halted shipments of its Novum IQ Large Volume Pump after reports of two deaths and multiple injuries, and said it does not expect to resume shipments before year-end. The medical products maker now expects adjusted earnings of between $2.42 and $2.52 per share, down from its prior view of $2.47 to $2.55 per share. Analysts had expected $2.52 per share. Hurricane Helene damaged Baxter's North Carolina plant last year, disrupting IV solution production and prompting hospitals to conserve fluids. While supply has since been restored, demand remains subdued, the company said. The company said volume declines in IV solutions significantly impacted operating income and profit per share, with the outlook assuming fluid conservation to remain at 20% below normal levels for the rest of 2025. "Many investors had feared this scenario given the lack of a pre-announcement following a new CEO in early July," JPMorgan analyst Robbie Marcus said. Second-quarter adjusted earnings came in at 59 cents per share, missing estimates of 61 cents. Revenue was $2.81 billion, just shy of the $2.82 billion expected. Baxter's pharmaceuticals unit also underperformed, with injectable drug sales down 1% and anesthesia sales falling by low double digits globally. On tariffs, Baxter lowered its estimated 2025 impact to $40 million, from a previous $60 million to $70 million.
Business Wire
27-05-2025
- Business
- Business Wire
BAXTER TO Present at Goldman Sachs 46th Annual Global Healthcare Conference 2025
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 on Tuesday, June 10, 2025. Joel Grade, Baxter's chief financial officer, is scheduled to present at 10:40 a.m. Eastern Time. The live webcast of Baxter's presentation can be accessed at and will be available for replay through Sunday, December 7, 2025. About Baxter At Baxter, we are everywhere healthcare happens – and everywhere it is going, with essential solutions in the hospital, physician's office and other sites of care. For nearly a century, our customers have counted on us as a vital and trusted partner. And every day, millions of patients and healthcare providers rely on our unmatched portfolio of connected solutions, medical devices, and advanced injectable technologies. Approximately, 38,000 Baxter team members live our enduring mission: to save and sustain lives. Together, we are redefining how care is delivered to make a greater impact today, tomorrow, and beyond. To learn more, visit and follow us on X, LinkedIn and Facebook.
Yahoo
27-05-2025
- Business
- Yahoo
BAXTER TO Present at Goldman Sachs 46th Annual Global Healthcare Conference 2025
DEERFIELD, Ill., May 27, 2025--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 on Tuesday, June 10, 2025. Joel Grade, Baxter's chief financial officer, is scheduled to present at 10:40 a.m. Eastern Time. The live webcast of Baxter's presentation can be accessed at and will be available for replay through Sunday, December 7, 2025. About Baxter At Baxter, we are everywhere healthcare happens – and everywhere it is going, with essential solutions in the hospital, physician's office and other sites of care. For nearly a century, our customers have counted on us as a vital and trusted partner. And every day, millions of patients and healthcare providers rely on our unmatched portfolio of connected solutions, medical devices, and advanced injectable technologies. Approximately, 38,000 Baxter team members live our enduring mission: to save and sustain lives. Together, we are redefining how care is delivered to make a greater impact today, tomorrow, and beyond. To learn more, visit and follow us on X, LinkedIn and Facebook. View source version on Contacts Media ContactSteve Brett, (224) 948-5353media@ Investor ContactClare Trachtman, (224) 948-3020 Sign in to access your portfolio
Yahoo
15-05-2025
- Business
- Yahoo
BAX Q1 Earnings Call: Revenue Tops Expectations, Margins Face Tariff and Cost Pressures
Healthcare company Baxter International (NYSE:BAX) reported revenue ahead of Wall Street's expectations in Q1 CY2025, with sales up 5.4% year on year to $2.63 billion. The company expects next quarter's revenue to be around $2.82 billion, close to analysts' estimates. Its non-GAAP profit of $0.55 per share was 14.8% above analysts' consensus estimates. Is now the time to buy BAX? Find out in our full research report (it's free). Revenue: $2.63 billion vs analyst estimates of $2.58 billion (5.4% year-on-year growth, 1.9% beat) Adjusted EPS: $0.55 vs analyst estimates of $0.48 (14.8% beat) Adjusted EBITDA: $639 million vs analyst estimates of $484.8 million (24.3% margin, 31.8% beat) Revenue Guidance for Q2 CY2025 is $2.82 billion at the midpoint, roughly in line with what analysts were expecting Management slightly raised its full-year Adjusted EPS guidance to $2.51 at the midpoint Operating Margin: 2.2%, down from 4.6% in the same quarter last year Free Cash Flow was -$315 million compared to -$13 million in the same quarter last year Constant Currency Revenue rose 7% year on year (2% in the same quarter last year) Market Capitalization: $15.55 billion Baxter International's first quarter results were primarily driven by robust sales growth across all its business segments, with notable outperformance in Medical Products & Therapies (MPT) and Healthcare Systems & Technologies (HST). Management attributed the top-line beat to increased demand for infusion systems, a strong recovery in IV solutions supply, and competitive wins in patient support systems. In addition, distributors began rebuilding inventory earlier than anticipated, and the company benefited from operational efficiencies, which helped offset ongoing cost pressures. Looking ahead, Baxter's guidance reflects both confidence in underlying business momentum and caution regarding external factors. Management highlighted persistent macroeconomic uncertainty, the impact of new and proposed global tariffs, and the ongoing transition following the sale of the Kidney Care business. CFO Joel Grade emphasized a continued focus on operational efficiency and targeted investments in innovation, while noting that new tariffs and foreign exchange headwinds are expected to weigh on margins for the remainder of the year. Baxter's leadership identified several key operational and market factors that shaped Q1 performance and set the context for the rest of the year. Strong segment growth, supply chain recovery, and competitive gains in core franchises were central themes. MPT Segment Outperformance: Medical Products & Therapies growth was supported by double-digit gains in U.S. infusion systems, led by the ongoing Novum IQ pump rollout. The business also benefited from improved supply and backorder clearance in nutrition products. IV Solutions Supply Recovery: The North Cove IV solutions facility returned to pre-disruption production levels, enabling removal of product allocations and prompting some hospitals and distributors to rebuild inventory ahead of schedule. Management expects continued conservation in hospital usage but anticipates normalization as allocations are lifted. HST Segment Momentum: Healthcare Systems & Technologies saw strong U.S. capital orders, particularly in Care and Connectivity Solutions. Management credited competitive wins in patient support and ICU product lines, as well as a healthy backlog supporting future growth. Tariff and Cost Mitigation Efforts: New global tariffs, particularly those affecting U.S. and China trade, emerged as a headwind. Management outlined mitigation strategies including supply chain optimization, selective pricing actions, and advocacy for product exemptions to offset estimated impacts. Ongoing Strategic Transformation: Baxter is transitioning following the sale of its Kidney Care business. Management highlighted ongoing cost containment efforts, reallocation of stranded costs, and investments in innovation, all intended to support long-term margin expansion and growth. Management's outlook for the coming quarters hinges on navigating macroeconomic headwinds, capitalizing on backlog strength, and executing operational improvements to drive sustainable growth and margin recovery. Tariff and FX Headwinds: The company expects new tariffs and adverse foreign exchange rates to pressure operating margins, with mitigation efforts only partially offsetting these impacts in the near term. Backlog and Capital Demand: A strong order book in Care and Connectivity Solutions and ongoing recovery in healthcare capital spending are expected to support revenue stability, though management is monitoring for demand shifts due to customer reimbursement challenges. Operational Efficiency and Innovation: Baxter is prioritizing supply chain optimization, targeted pricing, and accelerated investment in new product development to offset cost pressures and lay the groundwork for future margin expansion. Joanne Wuensch (Citi): Asked about specific mitigation strategies for tariffs and the sustainability of HST growth. Management detailed supply chain adjustments and targeted pricing, while maintaining a conservative outlook despite strong backlog. David Roman (Goldman Sachs): Queried the impact of IV solution allocation removal and long-term changes in hospital inventory practices. Management expects ongoing conservation but predicts gradual normalization as allocations end. Travis Steed (BofA Securities): Questioned margin pressures from cost reclassifications and the trajectory back to pre-pandemic margins. Management cited temporary impacts from MSA income and planning costs, with long-term margin expansion tied to innovation and product mix. Vijay Kumar (Evercore ISI): Sought clarification on the deceleration in Q2 growth and Novum IQ's market share gains. Management attributed Q2 guidance to ongoing IV solution conservation and built-in conservatism, while confirming Novum IQ has achieved low single-digit share gains. Pito Chickering (Deutsche Bank): Asked for a bridge between previous and updated EPS guidance given operational and tariff impacts, and probed drivers of U.S. CCS wins. Management pointed to strong operational execution offset by tariffs and FX, and highlighted commercial progress and digital enhancements in CCS. In the coming quarters, the StockStory team will track (1) progress on tariff mitigation and supply chain adjustments, (2) evidence of sustained order growth and backlog conversion in the HST segment, and (3) normalization in IV solutions demand as hospital inventory practices adjust. We will also monitor execution on new product launches and any updates on permanent CEO selection, as both could significantly affect Baxter's strategic direction. Baxter currently trades at a forward P/E ratio of 12×. In the wake of earnings, is it a buy or sell? Find out in our free research report. The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
